Sorrento reports positive clinical results for COVID-19 stem cell treatment
Sorrento said that all 10 of the COVID-19 patients receiving its stem cell treatment in a phase IB study were discharged from the intensive care unit within three days after their last infusion. Read More
Vertex, CRISPR Therapeutics ink deal on sickle cell gene therapy
Vertex Pharmaceuticals and CRISPR Therapeutics have amended their collaboration agreement to develop, manufacture, and commercialize CTX001, an ex vivo CRISPR/Cas9-based gene editing therapy being developed for the treatment of sickle cell disease and transfusion-dependent beta-thalassemia. Read More
Halo Labs launches Aura CL for cell therapy quality analysis
Halo Labs has launched Aura CL, a next-generation instrument to measure cell therapy product quality. Read More
Code Biotherapeutics launches to develop nonviral-based gene therapies
Code Biotherapeutics has launched with $10 million in financing and will focus on next-generation nonviral gene therapies. Read More
Lineage, Immunomic to develop glioblastoma immunotherapy
Lineage Cell Therapeutics and Immunomic Therapeutics have signed a worldwide license and development collaboration agreement to generate a novel candidate derived from Lineage's VAC allogeneic cancer immunotherapy platform, which targets a proprietary, tumor-associated antigen construct provided by Immunomic for the treatment of glioblastoma multiforme. Read More
Valo acquires PeptiBAC vaccine tech
Valo Therapeutics has acquired the intellectual property rights to the University of Helsinki's PeptiBAC cancer and infectious disease vaccination technology. Read More
ARMI launches new tech roadmap for pandemic response and recovery
The Advanced Regenerative Manufacturing Institute (ARMI) has released a document that outlines a technology-based plan for U.S. pandemic response and preparedness. Read More
Aegis Life starts Entos DNA COVID-19 vaccine clinical trial
Aegis Life, subsidiary of Entos Pharmaceuticals, has begun a phase I/II clinical trial of Entos' Covigenix VAX-001, a DNA COVID-19 vaccine. Read More
Adagio nabs $336M to develop COVID-19 antibody treatment/prophylactic
Adagio Therapeutics has secured $336 million that it plans to use to develop an antibody for the treatment and prevention of COVID-19. Read More
Tonix licenses SARS-CoV-2 antiviral inhibitor from OyaGen
Tonix Pharmaceuticals has agreed to obtain the exclusive worldwide license for TNX-3500 (previously OYA1), an antiviral inhibitor of SARS-CoV-2 developed by OyaGen, for the treatment of COVID-19 and potentially other viral disorders. Read More
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter